Eastern and South-Eastern Asia vs Luxembourg: Proportion of the target population who received the final dose of
Eastern and South-Eastern Asia
21.0%
in 2024
Luxembourg
79.0%
in 2024
Eastern and South-Eastern Asia rank
26th
Luxembourg rank
24th
Proportion of the target population who received the final dose of over time
- Eastern and South-Eastern Asia
- Luxembourg
How they compare
Luxembourg currently reports 79.0% against 21.0% in Eastern and South-Eastern Asia, a difference of 58.0%.
That makes Luxembourg's figure about 3.8 times Eastern and South-Eastern Asia's.
Across all 14 years both countries report, Luxembourg has been ahead every year.
Eastern and South-Eastern Asia ranks 26th and Luxembourg ranks 24th of 35 groups.
Luxembourg has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eastern and South-Eastern Asia | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3.1% | 26.6% | 23.4% | Luxembourg |
| 2020s | 8.8% | 75.2% | 66.4% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Eastern and South-Eastern Asia or Luxembourg?
- Luxembourg, at 79.0% against 21.0% in Eastern and South-Eastern Asia as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Eastern and South-Eastern Asia and Luxembourg?
- 58.0%, with Luxembourg ahead.
- How many years of comparable data are there for Eastern and South-Eastern Asia and Luxembourg?
- 14 years are reported by both, from 2011 to 2024.
- How do Eastern and South-Eastern Asia and Luxembourg rank globally for proportion of the target population who received the final dose of?
- Eastern and South-Eastern Asia ranks 26th and Luxembourg ranks 24th of 35 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.